Publications by authors named "A Koutras"
Background/aim: The prognostic role of tissue PD-L1 expression in endometrial cancer (EC) remains controversial. Moreover, its value in guiding anti-PD1/PD-L1 immunotherapy is questionable. The eventual role of soluble PD-L1 (sPD-L1), released by cancer tissue and circulating immune cells, is largely unexplored.
View Article and Find Full Text PDFThe increased metastatic ability of small-cell lung cancer (SCLC) necessitates the identification of new prognostic biomarkers for clinical evaluation during the disease course. Our previous research highlighted the clinical relevance of transcription factor JunB (JUNB), C-X-C chemokine receptor type 4 (CXCR4), and programmed cell death 1 ligand 1 (PD-L1) in breast and non-small cell lung cancer (NSCLC) patients. In the current study, we examined these biomarkers in circulating tumor cells (CTCs) and plasma-derived exosomes from 100 treatment-naïve SCLC patients.
View Article and Find Full Text PDFArticle Synopsis
- A 43-year-old woman developed both UVF and VVF after a total hysterectomy and initially tried conservative treatment, which didn't work.
- She then underwent a successful surgical procedure to correct the issues and has remained symptom-free for a year, highlighting the importance of recognizing and managing these rare fistula formations effectively.
The occurrence of multiple pregnancies is consistently and significantly linked to the growing use of assisted reproductive technology (ART). Even very young women opt for having multiple embryos implanted by medical professionals in order to increase the chances of a successful outcome. Our aim is to review the research on cesarean section rates and perinatal outcomes, like perinatal morbidity, risk of preterm delivery, and low birth weight (LBW) of neonates in multiple pregnancies that resulted from ART in comparison to those that were naturally conceived.
View Article and Find Full Text PDFArticle Synopsis
- Older patients with advanced hormone receptor-positive/HER2-negative breast cancer benefit from combining CDK4/6 inhibitors with standard endocrine therapy, according to recent studies.
- There is a higher risk of side effects from these inhibitors in older patients, leading to a trend of starting them on lower doses, although this practice lacks strong evidence.
- The IMPORTANT-trial aims